Figure 2.

Efficacy of low‐dose benzbromarone (LDBen) and low‐dose febuxostat (LDFeb) in patients with renal underexcretion–type gout. A and B, Proportion of participants with serum urate levels of <6.0 mg/dl (A) and <5.0 mg/dl (B) at weeks 4, 8, and 12 after the initiation of treatment. Values at the bottom of the bars show the number of participants and values at the top of the bars show the percentage of participants. C, Trend of serum urate level in the 2 groups at weeks 4, 8, and 12. D, Change in serum urate levels in the 2 groups at weeks 4, 8, and 12, calculated as Δ = (baseline serum urate level — visit serum urate level)/baseline serum urate level. Results at each timepoint in C and D are the mean ± SD. ** = P < 0.01.